These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 10448985)

  • 1. Epidemic meningococcal disease in New Zealand: epidemiology and potential for prevention by vaccine.
    Bremner C; Lennon D; Martin D; Baker M; Rümke H
    N Z Med J; 1999 Jul; 112(1091):257-9. PubMed ID: 10448985
    [No Abstract]   [Full Text] [Related]  

  • 2. New Zealand's epidemic of meningococcal disease described using molecular analysis: implications for vaccine delivery.
    Dyet K; Devoy A; McDowell R; Martin D
    Vaccine; 2005 Mar; 23(17-18):2228-30. PubMed ID: 15755601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The New Zealand Meningococcal Vaccine Strategy: a tailor-made vaccine to combat a devastating epidemic.
    Sexton K; Lennon D; Oster P; Crengle S; Martin D; Mulholland K; Percival T; Reid S; Stewart J; O'Hallahan J
    N Z Med J; 2004 Aug; 117(1200):U1015. PubMed ID: 15475985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of group B meningococcal disease by vaccination: a difficult task.
    Thomas M
    N Z Med J; 2004 Aug; 117(1200):U1016. PubMed ID: 15475986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis.
    Holst J; Martin D; Arnold R; Huergo CC; Oster P; O'Hallahan J; Rosenqvist E
    Vaccine; 2009 Jun; 27 Suppl 2():B3-12. PubMed ID: 19481313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The concept of "tailor-made", protein-based, outer membrane vesicle vaccines against meningococcal disease.
    Holst J; Feiring B; Naess LM; Norheim G; Kristiansen P; Høiby EA; Bryn K; Oster P; Costantino P; Taha MK; Alonso JM; Caugant DA; Wedege E; Aaberge IS; Rappuoli R; Rosenqvist E
    Vaccine; 2005 Mar; 23(17-18):2202-5. PubMed ID: 15755595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Meningococcal disease in Ironville.
    Commun Dis Rep CDR Wkly; 1999 Aug; 9(34):297. PubMed ID: 10502876
    [No Abstract]   [Full Text] [Related]  

  • 8. Evaluating the post-licensure effectiveness of a group B meningococcal vaccine in New Zealand: a multi-faceted strategy.
    Ameratunga S; Macmillan A; Stewart J; Scott D; Mulholland K; Crengle S;
    Vaccine; 2005 Mar; 23(17-18):2231-4. PubMed ID: 15755602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outbreaks of group B meningococcal disease--Florida, 1995 and 1997.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 1998 Oct; 47(39):833-7. PubMed ID: 9780239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MeNZB vaccine and epidemic control: when do you stop vaccinating?
    Loring BJ; Turner N; Petousis-Harris H
    Vaccine; 2008 Nov; 26(47):5899-904. PubMed ID: 18804134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. From secondary prevention to primary prevention: a unique strategy that gives hope to a country ravaged by meningococcal disease.
    O'Hallahan J; Lennon D; Oster P; Lane R; Reid S; Mulholland K; Stewart J; Penney L; Percival T; Martin D
    Vaccine; 2005 Mar; 23(17-18):2197-201. PubMed ID: 15755594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Experience with the immunoprophylaxis of meningococcal infection in military collectives].
    Efimov EI
    Voen Med Zh; 1989 Apr; (4):49. PubMed ID: 2503934
    [No Abstract]   [Full Text] [Related]  

  • 13. [Immunoprophylaxis of meningococcal infection among the troops].
    Khokhlov DT; Efimov EI
    Voen Med Zh; 1984 Oct; (10):51-3. PubMed ID: 6438904
    [No Abstract]   [Full Text] [Related]  

  • 14. [Why and when to vaccinate against meningococcal disease].
    Humble M
    Nord Med; 1984; 99(10):248-50, 253. PubMed ID: 6436785
    [No Abstract]   [Full Text] [Related]  

  • 15. Meningococcal disease: a review on available vaccines and vaccines in development.
    Bröker M; Fantoni S
    Minerva Med; 2007 Oct; 98(5):575-89. PubMed ID: 18043565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serogroup B meningococcal disease: new outbreaks, new strategies.
    Wenger JD
    JAMA; 1999 Apr; 281(16):1541-3. PubMed ID: 10227326
    [No Abstract]   [Full Text] [Related]  

  • 17. The role of MeNZB vaccination in controlling the New Zealand meningococcal epidemic.
    Lennon D
    N Z Med J; 2008 Mar; 121(1270):110-2. PubMed ID: 18364765
    [No Abstract]   [Full Text] [Related]  

  • 18. The worldwide prevention of meningococcal infection. Still an elusive goal.
    Harrison LH
    JAMA; 1995 Feb; 273(5):419-21. PubMed ID: 7823389
    [No Abstract]   [Full Text] [Related]  

  • 19. Meningococcal disease and prevention at the Hajj.
    Borrow R
    Travel Med Infect Dis; 2009 Jul; 7(4):219-25. PubMed ID: 19717104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The strategy to control New Zealand's epidemic of group B meningococcal disease.
    O'Hallahan J; Lennon D; Oster P
    Pediatr Infect Dis J; 2004 Dec; 23(12 Suppl):S293-8. PubMed ID: 15597072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.